NICE Turns Around to Support the Use of Celgene's Revlimid

The cost regulator for the NHS in England and Wales has said that Celgene's Revlimid should be an option for treating patients with a particular form of myelodysplastic syndromes.

In new final draft guidance, the National Institute for Health and Care Excellence (NICE) has recommended use of Revlimid (lenalidomide) in a specific type of MDS that is characterised by a chromosomal abnormality called an isolated deletion 5q cytogenetic abnormality. Currently, the main treatment option for people with this kind of MDS is best supportive care including regular blood transfusions.

In earlier draft guidances published this May and in June last year, NICE had not backed Revlimid in this use because, while the Institute’s appraisal committee had found it to be an effective therapy, the data provided by Celgene showed uncertainty about whether it actually extended lives. The June 2013 draft guidance had also opened a consultation.

Link to the original report:

Source: PharmaTimes